Skip to main content

Table 3 Genetic features and clinical outcome of ABL-class or JAK-STAT pathway fusion (AJS)-positive patients

From: Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach – a population-based study

Case no. Age group In-frame gene fusion WBC DEX / PREDNI MRD D15 MRD D29 MRD D79 Risk Group alloSCT (Y/N) Event (Y/N) Comment
Case 1 Adult ETV6-ABL1 270 DEX N Y Induction death
Case 2 Adult ZC3HAV1-ABL2 72 PREDNI 30.5% 6.5% 0.01% IR Y Y Death of sepsis after alloSCT in CR1
Case 3 Adult EBF1-PDGFRB 258 DEX 45.3% 0.93% (POST A1) 0.7% (POST B1) HR-SCT Y Y Relapse after alloSCT and death
Case 4 Adult IGH-CRLF2 4 PREDNI 11.6% 20.3% 3.4% HR-SCT Y Y Relapse after alloSCT and alive in CR2
Case 5 Adult IGH-CRLF2 104 DEX 44.3% 8% 1.65% HR-SCT Y N Alive after alloSCT in CR1
Case 6 Pediatric IGH-CRLF2 35 PREDNI 0.22% < 0.1% 0.3% HR-SCT Y N Alive after alloSCT in CR1
Case 7 Pediatric BCR-JAK2 5 PREDNI 1.8% 0.33% < 0.1% IR N N Alive in CR1
  1. WBC White blood cells, DEX Dexamethasone, PREDNI Prednisolone, D15 Day 15, D29 Day 29, D79 Day 79, MRD Minimal residual disease, alloSCT Allogenic stem cell transplant, CR1 First clinical remission, CR2 Second clinical remission